Recruiting
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
ClinicalTrials.gov IDNCT02253251
PhaseNot Applicable
Enrollment15000
SponsorMiraKind
Age18 Years
SexALL
Conditions studied
Cancer
About this study
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
Interventions
- Genetic: KRAS-variant and microRNA binding site mutation testing — Participant in these studies will be tested for the KRAS-variant
Primary outcomes
- Measuring the prevalence of the KRAS-variant in certain populations Prevalence of the KRAS-variant in BRCA negative breast cancer patients (1 year)
- Comparing the impact of interventions in KRAS-variant versus non-KRAS variant populations (1 year)
Eligibility information
Inclusion Criteria:
* Personal or family history of cancer
* Personal history of endometriosis, or autoimmunity
Exclusion Criteria:
* Younger than 18
* Non-english speaking and unable to understand and sign the consent
Study locations
- MiraKind, Los Angeles, California 90025 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.